Loading
Life sciences · Interventional Study
ClinicalTrials.gov · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04559334). This is a study registration, not published results. Lead sponsor: Boston Children's Hospital. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 15 participants (ACTUAL). Conditions: Central Line Complication, Central Line-associated Bloodstream Infection (CLABSI). Interventions: DEVICE: Tetrasodium EDTA Catheter Lock Solution. Primary outcome measures: Number of Central Venous Catheter Occlusion Events During Tetrasodium EDTA Lock Therapy , 24 months before treatment initiation and 24 months after treatment initiation.; Number of Central Venous Catheter Breakage Events During Tetrasodium EDTA Lock Therapy , 24 months before treatment initiation and 24 months after treatment initiation.. Brief summary: In this research study we want to learn more about a study drug, tetrasodium sodium EDTA (Kitelock™) for maintaining the patency (blood flow) through a central venous catheter. Catheter occlusions such as blood clots have been shown to increase the risk of central line-associated bloodstream infection (CLABSI). This treatment consists of instilling a daily a dose of a solution , similar to heparin or saline lock flushes, into the catheter when it is not in use. The aim is to prevent CLABSI without increasing complications such as catheter breakage.